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Binary values were obtained using a threshold, which based on
the mean survival time of patients derived from literature.
RESULTS: Back-propagation as well as fuzzy-logic neural net-
works were applied. A 10-fold cross validation method was used
to obtain the appropriate models. Final results were compared
with the generic, logistic regression-based model. The best pre-
diction score of the ANN model was 82% (generalization) and
was higher than logistic regression prediction rate. Best obtained
model was tested under its practical application in the in-silico
study to model switching from cisplatin to carboplatin therapy
in NSCLC. The results demonstrate that thanks to the better sur-
vival rate such operations could be cost-effective. CONCLU-
SIONS: Artiﬁcial Neural Networks could be applied in
pharmacoeconomics analysis as additional modeling tools.
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OBJECTIVES: To analyze the risk of re-hospitalization for
COPD following different treatment regimens. METHODS: A
retrospective cohort study with data from the Dutch PHARMO
system, including medication and hospital admission records of
1.6 million inhabitants of 34 Dutch cities was performed.
Patients >40yrs with a ﬁrst admission for COPD during
1992–2002 were identiﬁed. Treatment was assessed in the period
of 90 days following ﬁrst discharge. Cox proportional hazard
analysis was performed to analyze the time to re-hospitalization
for COPD for different treatment regimes. Hazard rate (HR) and
95% conﬁdence intervals (CI) were adjusted for potential risk
factors including gender, age, year of hospitalization and disease
severity. The maximum follow-up time was two years.
RESULTS: From the total cohort of 3855 patients, 1118 (29%)
were re-hospitalized within two years after the ﬁrst hospitaliza-
tion. The mean period to re-hospitalization was 230 days. Com-
pared to ICS as a reference group, an increased risk for
re-hospitalization was found in the following treatment groups:
theophylline (HR 1.83, CI 1.12–2.99), and ICS combined with
anticholinergics and beta-agonists (HR 1.50, CI 1.02–2.20).
CONCLUSIONS: This study found re-hospitalizations occurred
in approximately one-third (1/3) of patients. Differences in
COPD re-hospitalization risks between treatment groups were
observed. Anti-inﬂammatory therapy alone demonstrated a sig-
niﬁcant protective effect compared to theophylline therapy alone
or a combination therapy of ICS, anticholinergics and beta-
agonists.
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OBJECTIVE: To identify items in the existing disease-speciﬁc St.
George’s Respiratory Questionnaire (SGRQ) that might be suit-
able for use in a COPD speciﬁc utility instrument. METHOD:
The SGRQ has three domains. We planned to use three items per
domain (mild, moderate and severe) for the new instrument.
Using data from 893 patients we ﬁrst reduced the original 50
SGRQ items to the 40 “best” items using classical test methods
and Rasch modelling (RUMM 2010 software). The Person Sep-
aration Index for these 40 items was 0.9 (an “excellent” ﬁt to a
unidimensional model). We then used Rasch location maps to
identify suitable items. We examined those items that covered
95% of the patients, then divided the population into tertiles
according to their person location value: mild (mean location 
-0.97 logits, SD = 0.35), moderate (mean location 0.09 logits,
SD = 0.39), severe (mean location 1.45 logits, SD = 0.56). For
each level of patient severity we chose one item per SGRQ
domain using criteria based upon quality of ﬁt of the item to the
unidimensional model of all 40 items. RESULTS: We were able
to identify one suitable item per domain at each severity level.
The locations of the nine items ranged from -1.16 logits to 1.47
logits. The mean item location for the three mild items was 
-0.55 logits, moderate items 0.18 logits, severe items 1.16 logits.
CONCLUSION: We have now identiﬁed nine items from three
domains of health in COPD. Each item has a clearly deﬁned level
of severity. This approach should ensure that the utility instru-
ment, when fully developed, has good discriminative properties
and may also have good evaluative properties.
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OBJECTIVES: The purpose of this study is to establish a
measure of the COPD severity using claims data. METHODS:
The study sample was identiﬁed from a large claims database
covering the period 1999–2002. Patients of age 18–65 with pre-
vious acute exacerbation of COPD (AECB) were included in 
the study sample (n = 2068). Variables associated with COPD
severity were extracted. Variables with low face validity, high
endorsement rate (>97%), or low homogeneity (measured by
Chronbach’s alpha) were excluded. Principal component analy-
sis with orthogonal solution was conducted to identify the latent
severity score. Scree test and eigenvalue-one criterion were used
to determine the number of latent factors. The severity score was
standardized (mean = 50, SD = 10). Construct validity was tested
by comparing severe COPD patients to moderate/mild patients
of 3-month AECB incidence rate and by comparing the failure
rate (ER/hospitalization) of antibiotic treatment in AECB.
RESULTS: Six variables were excluded from the original 18
potential variables due to low face validity or high endorsement
rate. Principal component analysis based on the remaining 12
variables produced a single latent factor (eigenvalue = 3.6), there-
fore no factor rotation was performed. The score loaded high on
the use of oxygen therapy, corticosteroids, and bronchodilators,
etc. The resulting factor loading agreed with the clinical recom-
mendation in GOLD criteria of treating COPD by severity.
Chronbach’s alpha test showed good homogeneity of the sever-
ity score (0.71) and no input variables were rejected. The con-
struct validity tests showed that, compared with mild/moderate
COPD patients, severe patients were about 3 times more likely
to have AECB episodes and 60% more likely to have antibiotic
treatment failure in AECB episodes. CONCLUSIONS: The
COPD severity score developed in this study can be applied to a
wide range of retrospective studies of COPD, where results from
